Deadline Looms for Viatris Investors: What You Need to Know Before June 3rd

Here’s the deal: If you’re holding Viatris (VTRS) stock, you need to pay close attention to the clock right now. A major legal showdown is unfolding, and investors who owned the stock between August 2024 and February 2025 have a rapidly approaching deadline to stake their claim in a class-action lawsuit. Let’s break down what’s at stake—and why this isn’t just another corporate scandal.

First, the facts: Faruqi & Faruqi, LLP—a powerhouse in securities litigation—has filed a federal class-action lawsuit accusing Viatris of misleading investors about its operational and financial health. The crux of the case centers on the company’s Indore, India facility, which regulators flagged for repeated FDA violations. According to the lawsuit, Viatris allegedly downplayed the severity of these issues, assuring shareholders that the problems were “manageable” while secretly facing production shutdowns and delayed shipments of critical drugs like Lenalidomide.

Then, on February 27, 2025, the truth hit the market like a sledgehammer. Viatris revealed its fiscal 2024 results, slashing its 2025 guidance and admitting the Indore facility’s regulatory hell had gutted its financial outlook. The stock tanked 15.21% in a single day, dropping from $11.24 to $9.53.

Let’s take a look at the numbers: . That plunge from $11.24 to $9.53 in a single day is a red flag. But here’s the kicker—the lawsuit argues those drops were entirely avoidable if Viatris had been honest sooner.

Now, the legal clock is ticking. Investors who bought VTRS shares between August 8, 2024, and February 26, 2025, have until June 3, 2025, to file to become the lead plaintiff in this case. That’s not just a formality: the lead plaintiff effectively steers the lawsuit and can influence how the case unfolds. But here’s the catch—the lead plaintiff must have the “biggest dog in the fight,” meaning the largest financial stake.

So, what does this mean for you? If you’re an investor in VTRS during that period, you have two choices:

1. Act by June 3: If you’ve got significant losses, contact Faruqi & Faruqi. Even if you’re not lead plaintiff, you could still share in any settlement.
2. Wait and Regret: Let the deadline pass, and you’ll lose your say.

But here’s the bigger picture: This isn’t just a legal battle—it’s a wake-up call for investors in pharma stocks. Viatris isn’t the first company to downplay regulatory risks (see: Valeant, Theranos), but the scale here is massive. The Indore facility isn’t some minor outpost—it’s a linchpin for Viatris’s generics business, which fuels its entire revenue engine.

The numbers don’t lie. . The stock’s post-announcement freefall isn’t just about one bad quarter—it’s about trust. And once that’s gone, it’s nearly impossible to rebuild.

In the end, this case underscores a brutal truth: In investing, transparency is everything. When companies spin regulatory issues into “speed bumps,” investors get run over. The June 3 deadline isn’t just for lawyers—it’s a chance for shareholders to hold Viatris accountable.

Final Verdict: If you’re a VTRS investor, June 3 is your last chance to make your voice heard. The math is clear: The stock’s collapse and the firm’s track record in class actions (Faruqi has recovered $700 million+ since 1995) suggest this isn’t a frivolous lawsuit. Act fast, or risk being left holding the bag—and not just metaphorically.

This article is for informational purposes only and does not constitute financial advice. Consult a licensed professional before making investment decisions.